Biotech stocks are surging, driven by clinical wins, M&A and new drug technologies
Biotech stocks are rallying, with the iShares Biotechnology ETF (IBB) up 24% year-to-date and Moderna surging 587%. Analysts attribute the boom to clinical trial successes, increased M&A activity, and advancements in new drug technologies such as genomics, mRNA, and AI. The global AI in drug discovery market is projected to grow from $20 billion in 2025 to over $160 billion by 2035. Biopharma dealmaking reached $134 billion in the first half of 2026, up from $112 billion for all of 2025.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
1SWAP Token: Project Status, Historical Review, and Market Analysis
-
2
MOOLAH Coin: A BEP20 Token on BNB Chain and Its Trading Guide
-
3
China's Cryptocurrency Regulatory Landscape and the Global Exchange Ecosystem
-
4
DCN (Dentacoin) Value Analysis: Is It Worth Long-Term Investment?
-
5
KENSHI (KNS) Analysis: Web3 Data Platform and Its Trading Status
-
6
IMMO Coin Analysis: What is ImmortalDAO Finance (IMMO) and Where to Trade It
-
7
Zeus Network (ZEUS) Token Analysis and Trading Status
-
8
ELA Coin (Elastos) Status and Historical Review: 2023-2025 Forecasts and Actual Performance
-
9
BNT Coin: Total Supply and Current Status Analysis
-
10
AI build-out faces turmoil as Solidigm pulls IPO, neoclouds slump and credit risks mount
Markets Today
Recommended Reading











